阿育吠陀是一门治疗疾病根源的整体科学。一种疾病可以成为另一种疾病的致病因素。这个概念基本上被描述为阿育吠陀的NidanarthakarVyadhi。以同样的方式,治疗致病疾病有助于管理其他疾病。然而,存在许多关于阿育吠陀治疗支气管哮喘和痔疮的临床试验。缺乏已发表的病例报告或临床试验表明Arsha(痔疮)和Shwasa(支气管哮喘)之间存在关联。本病例报告对痔疮及其治疗在支气管哮喘发病机制和治疗中的作用提出了重要观点。此病例报告,一名38岁的女性患者已知支气管哮喘病例,该病例来到Kayachikitsa政府Ayurved学院和医院的OPD,那格浦尔有痰咳嗽的抱怨,呼吸困难,胸痛(开/关)三年。这些症状的严重程度增加了三个月。患者接受常规ShwasghnaChikitsa(治疗支气管哮喘)治疗五天,但反应并不令人满意。经过五天的Shwasghna治疗,患者有痔疮病史。考虑到NidanarthakarRoga(一种疾病可以导致另一种疾病),治疗是有计划的。治疗原则是治疗致病性疾病(Arsha)。因此,添加了Arshoghna治疗。峰值呼气流速(PEFR)显著增加,持续的最小灵感(SMI),并观察了改良的医学研究委员会呼吸困难量表(mMRC)。呼吸频率也从28/min降至18/min。观察到患者主观和客观参数的改善。纳入Arsha治疗有助于Tamakshwas(支气管哮喘)的治疗。有必要在这个方向上进行进一步的研究。
Ayurveda is a holistic science that treats root cause of diseases. One disease can become a causative factor for another disease. This concept is fundamentally described as Nidanarthakar Vyadhi in Ayurveda. In the same way, treating causative diseases is helpful in managing another diseases. However, many published clinical trials on Ayurveda management of Bronchial asthma and Hemorrhoids exist. There is a dearth of published
case reports or clinical trials showing an association between Arsha (
hemorrhoids) and Shwasa (bronchial asthma). This
case report gives important viewpoints about the role of
hemorrhoids and its treatment in pathogenesis and treatment of bronchial asthma. This
case report of a 38-year-old female patient known
case of bronchial asthma who came to the OPD of Kayachikitsa Government Ayurved College and Hospital, Nagpur with complaints of cough with sputum, breathlessness, chest pain (on/off) for three years. The severity of these symptoms increased for three months. The patient was treated with conventional Shwasghna Chikitsa (treatment of bronchial asthma) for five days, but the response was unsatisfactory. After five days of Shwasghna treatment, the patient gave a history of
hemorrhoids. Considering Nidanarthakar Roga (one disease can cause of another disease), treatment was planned. The treatment principle is the treatment of causative disease (Arsha). Hence, Arshoghna treatment was added. Significant increases in peak expiratory flow rate (PEFR), Sustained minimal inspiration (SMI), and Modified Medical Research Council Dyspnoea scale (mMRC) were observed. The respiratory rate was also reduced from 28/min to 18/min. Improvement in the subjective and objective parameters of the patient was observed. The inclusion of Arsha treatment can be helpful in the management of Tamakshwas (Bronchial Asthma). The need for further research in this direction is warranted.